CTLA4 and diabetes mellitus: Additionally, it was observed that lower plasma levels of antibodies were present with PIGF2-PDL1 or PIGF2-CTLA4 treatment, and no mice (nonobese diabetic mice) developed diabetes with PIGF2-PDL1 treatment compared to 100% diabetes incidence in the unconjugated anti-PD-L1 treatment group [132].